| A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ... EMBO molecular medicine 10 (12), e9172, 2018 | 207 | 2018 |
| Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III … R Dienstmann, G Villacampa, A Sveen, MJ Mason, D Niedzwiecki, ... Annals of oncology 30 (10), 1622-1629, 2019 | 173 | 2019 |
| Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis M Ligero, O Jordi-Ollero, K Bernatowicz, A Garcia-Ruiz, ... European radiology 31, 1460-1470, 2021 | 106 | 2021 |
| Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria I Matos, J Martin-Liberal, A García-Ruiz, C Hierro, M Ochoa de Olza, ... Clinical Cancer Research 26 (8), 1846-1855, 2020 | 87 | 2020 |
| Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma G Iacoboni, G Villacampa, N Martinez‐Cibrian, R Bailén, L Lopez Corral, ... Cancer Medicine 10 (10), 3214-3223, 2021 | 86 | 2021 |
| Advanced-stage non–small cell lung cancer: advances in thoracic oncology 2018 J Remon, MJ Ahn, N Girard, M Johnson, DW Kim, G Lopes, RN Pillai, ... Journal of Thoracic Oncology 14 (7), 1134-1155, 2019 | 71 | 2019 |
| A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors M Ligero, A Garcia-Ruiz, C Viaplana, G Villacampa, MV Raciti, J Landa, ... Radiology 299 (1), 109-119, 2021 | 65 | 2021 |
| Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma G Iacoboni, K Rejeski, G Villacampa, JA van Doesum, A Chiappella, ... Blood advances 6 (12), 3606-3610, 2022 | 56 | 2022 |
| Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto … A Llop-Guevara, S Loibl, G Villacampa, V Vladimirova, A Schneeweiss, ... Annals of Oncology 32 (12), 1590-1596, 2021 | 56 | 2021 |
| Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis A Papakonstantinou, NS Gonzalez, I Pimentel, A Suñol, E Zamora, C Ortiz, ... Cancer Treatment Reviews 104, 102362, 2022 | 51 | 2022 |
| Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes J Montoro, L Gallur, B Merchán, A Molero, E Roldán, F Martínez-Valle, ... Annals of hematology 97, 1349-1356, 2018 | 51 | 2018 |
| RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer E Elez, J Ros, J Fernández, G Villacampa, AB Moreno-Cárdenas, ... Nature medicine 28 (10), 2162-2170, 2022 | 50 | 2022 |
| Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies M Jiménez, E Roldán, C Fernández-Naval, G Villacampa, ... Blood Advances 6 (3), 774-784, 2022 | 46 | 2022 |
| Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC) P Abrisqueta, J Delgado, M Alcoceba, AC Oliveira, J Loscertales, ... British journal of haematology 190 (6), 854-863, 2020 | 45 | 2020 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial SM Tolaney, P Tarantino, N Graham, N Tayob, L Parè, G Villacampa, ... The Lancet Oncology 24 (3), 273-285, 2023 | 44 | 2023 |
| Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification B Pellegrino, A Herencia-Ropero, A Llop-Guevara, F Pedretti, ... Cancer research 82 (8), 1646-1657, 2022 | 44 | 2022 |
| High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer M Palafox, L Monserrat, M Bellet, G Villacampa, A Gonzalez-Perez, ... Nature communications 13 (1), 5258, 2022 | 41 | 2022 |
| Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy G Iacoboni, M Simó, G Villacampa, E Catalá, C Carpio, C Díaz-Lagares, ... Annals of hematology 100 (9), 2303-2310, 2021 | 37 | 2021 |
| MET alterations in NSCLC—current perspectives and future challenges J Remon, LEL Hendriks, G Mountzios, R García-Campelo, SPL Saw, ... Journal of Thoracic Oncology 18 (4), 419-435, 2023 | 33 | 2023 |
| ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma H Verdaguer, T Saurí, DA Acosta, M Guardiola, A Sierra, J Hernando, ... Clinical Cancer Research 28 (8), 1662-1671, 2022 | 30 | 2022 |
